Intero Biosystems wants drugmakers to test on mini human intestines, not animals

Intero Biosystems' approach addresses a recognized limitation in drug development: animal models often fail to accurately predict human responses, leading to high failure rates in clinical trials. By creating organoids that contain multiple human intestinal cell and tissue types, the company aims to offer a more biologically relevant testing model than simpler in-vitro methods or animal studies. This relevance is crucial for assessing drug safety and efficacy earlier in the development process.

The startup's emergence aligns with a broader shift in regulatory attitudes, particularly in the United States. The U.S. Food and Drug Administration (FDA)'s recent initiatives to reduce reliance on animal testing, including promoting alternatives like organoids and providing guidance for validating New Approach Methodologies (NAMs), indicate a growing acceptance of non-animal models. This regulatory encouragement appears to be influencing pharmaceutical companies, making them more willing to explore technologies such as organoids.

Intero Biosystems has generated over $400,000 in revenue from the fourth quarter of last year through the third quarter of this year, serving under ten customers. While gaining early traction, the company operates in a competitive landscape with other firms like Altis Biosystems and InSphero also developing human-relevant gut models. Intero's ability to scale production and expand its organoid technology will be key to distinguishing itself and capturing a larger share of this evolving market.